| Title |
Brentuximab Vedotin in CD30+ Lymphomas
|
|---|---|
| Published in |
Biologics in Therapy, March 2013
|
| DOI | 10.1007/s13554-013-0008-7 |
| Pubmed ID | |
| Authors |
Guilherme Fleury Perini, Barbara Pro |
| Abstract |
Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 33 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 15% |
| Student > Master | 5 | 15% |
| Student > Doctoral Student | 5 | 15% |
| Student > Bachelor | 5 | 15% |
| Student > Ph. D. Student | 4 | 12% |
| Other | 8 | 24% |
| Unknown | 2 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 32% |
| Agricultural and Biological Sciences | 6 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 15% |
| Chemistry | 5 | 15% |
| Engineering | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 2 | 6% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2013.
All research outputs
#18,331,227
of 22,699,621 outputs
Outputs from Biologics in Therapy
#12
of 20 outputs
Outputs of similar age
#147,552
of 194,016 outputs
Outputs of similar age from Biologics in Therapy
#2
of 2 outputs
Altmetric has tracked 22,699,621 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 20 research outputs from this source. They receive a mean Attention Score of 2.2. This one scored the same or higher as 8 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,016 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.